carbamazepine oxcarbazepine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metabolic Clearance Rate
Conditions
Metabolic Clearance Rate
Trial Timeline
Apr 1, 2005 → Oct 1, 2006
NCT ID
NCT00260247About carbamazepine oxcarbazepine
carbamazepine oxcarbazepine is a approved stage product being developed by Novartis for Metabolic Clearance Rate. The current trial status is completed. This product is registered under clinical trial identifier NCT00260247. Target conditions include Metabolic Clearance Rate.
What happened to similar drugs?
18 of 20 similar drugs in Metabolic Clearance Rate were approved
Approved (18) Terminated (4) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00260247 | Approved | Completed |
Competing Products
20 competing products in Metabolic Clearance Rate